ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2017
Expenditure of hospital care on cancer in China, from 2011 to 2015.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.BMC health services research · 2023Trial
- A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China.BMC public health · 2025Article
- Effectiveness of early cancer screening and diagnosis in urban China.Scientific reports · 2025Article
- Analysis and projection of the disease burden of nasopharyngeal carcinoma in China based on the GBD database.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
- Association among financial toxicity, depression and fear of cancer recurrence in young breast cancer patient-family caregiver dyads: an actor-partner interdependence mediation model.BMC psychiatry · 2025Article
- Cost Shifting in Lung Cancer Inpatient Care Under Diagnosis-Intervention Packet Reform: A Pilot Study in China.Risk management and healthcare policy · 2025Article
- The shift of expenditure of medical service for diagnosis and treatment of colorectal cancer from 2005 to 2014: a hospital-based retrospective survey in Guangxi.Frontiers in public health · 2025Article
- Medical treatment cost for Chinese inpatients with colorectal cancer by sites.Frontiers in public health · 2025Observational
- Information needs preferences of Chinese colorectal cancer patients receiving chemotherapy: A discrete choice experiment.Asia-Pacific journal of oncology nursing · 2024Article
- Article
- Estimating the economic burden of colorectal cancer in China, 2019-2030: A population-level prevalence-based analysis.Cancer medicine · 2024Article
- Cancer Survival Trends in Southeastern China, 2011-2021: A Population-Based Study.Clinical epidemiology · 2024Article
- Health insurance as a moderator in the relationship between financial toxicity and medical cost-coping behaviors: Evidence from patients with lung cancer in China.Cancer medicine · 2024Article
- Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy.BMJ (Clinical research ed.) · 2023Article
- Financial toxicity following surgical treatment for colorectal cancer: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Article
- Lung cancer incidence and mortality in China: Updated statistics and an overview of temporal trends from 2000 to 2016.Journal of the National Cancer Center · 2022Article
- The population-level economic burden of liver cancer in China, 2019-2030: prevalence-based estimations from a societal perspective.Cost effectiveness and resource allocation : C/E · 2022Article
- A Risk-Factor Model for Antineoplastic Drug-Induced Serious Adverse Events in Cancer Inpatients: A Retrospective Study Based on the Global Trigger Tool and Machine Learning.Frontiers in pharmacology · 2022Article
- Timely Estimates of 5-Year Relative Survival for Patients With Cervical Cancer: A Period Analysis Using Cancer Registry Data From Taizhou, Eastern China.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA solid understanding of levels and trends of spending on cancer is important to evaluate whether our healthcare resources were wisely spent and to prioritize future resources for cancer treatment and prevention. However, studies on economic burden of cancers in China are scant and the results are inconsistent.
methodsThe Chinese hospital information database and nearly 350 million inpatient medical record data were used. As the ratios of cancer inpatient payments to total inpatient payments were mainly influenced by the grades and sites of hospitals, the estimates of payments of cancer inpatients in this study were stratified by hospital grades and provinces. Only the payments of cancer inpatients happened in grade 2, grade 3 and specialized cancer hospitals were included in the analyses. The total medical payments of cancers in China were estimated based on the ratios of outpatient payments to inpatient payments in specialized cancer hospitals.
resultsFrom 2011 to 2015, the payments of cancer inpatients in China have increased by 84.1% and the total inpatient payments reached 177.1 billion RMB in 2015, accounting for 4.3% of the total health expenditure in China. Based on the ratio of outpatient payments to inpatient payments, the total payments on cancer treatments in China were estimated to be 221.4 billion RMB in 2015. Among different cancer types, the highest payments were the treatment of trachea, bronchus and lung cancer. The major cancer inpatient payments (67.1% in 2015) spent in grade 3 general hospitals and this ratio increased continually from 2011 to 2015. The expenditure of cancer treatments also varies by region with the major expenditure in the eastern region of China.
conclusionsThis study estimated the total payments of cancer treatments in China and analyzed how the money was spent on cancer treatments in the recent 5 years, which would provide information for decision makings on the allocation of resources to service provisioning, prevention strategies, research funding, and assessing whether the economic burden of cancer is affordable to the governments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.